Dr. Margaret Dugan, a Clinical Oncology Drug Development Expert, Joins Our Scientific Advisory Board
“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
We are excited to announce that Dr. Margaret Dugan has joined General Proximity's Scientific Advisory Board. Dr. Dugan brings 30+ years of experience in clinical oncology drug development and has been directly involved in numerous regulatory filings, including drug approvals for Femara® and Ceritinib.
Dr. Dugan is currently the Chief Medical Officer (CMO) at Schrödinger, where she is responsible for clinical and regulatory development. Prior to joining Schrödinger, Margaret served as CMO of Dracen Pharmaceuticals, an oncology company. During her career, she has held roles of increasing responsibility, including serving as a senior vice president at Novartis, where she led oncology-focused global strategic drug development for over 15 years.
Dr. Dugan’s translatable drug development expertise will be invaluable as we continue to advance our innovative programs closer to the clinic. Please join us in welcoming her to the General Proximity team!
